Semax

Name: Semax
Availability: InStock

5mg vial

Semax is a synthetic heptapeptide analogue of ACTH(4-10), developed in Russia and used clinically there for stroke recovery, cognitive enhancement and optic-nerve disorders. It is one of the most extensively studied nootropic peptides, with documented neuroprotective and neurotrophic effects.

Select size

Checking availability…

Researched for

Significant neuroprotection in ischaemic stroke research
Sustained BDNF and NGF upregulation supporting neuroplasticity
Improved attention, working memory and executive function
Improved recovery outcomes in optic-nerve and CNS-injury research
Modulation of dopaminergic systems supporting motivation and mood
Favourable safety profile in Russian clinical use

Mechanism of action

Upregulates BDNF and NGF expression, modulates dopaminergic and serotonergic transmission, and inhibits enkephalin-degrading enzymes. Demonstrates neuroprotective effects via reduced excitotoxicity and oxidative stress.

Research protocol

Common research protocols use 250–600mcg intranasally 1–3× daily, or subcutaneously at similar doses. Cycles typically run 2–4 weeks with breaks. Higher doses (up to 1200mcg/day) appear in stroke-recovery research.

Half-life

Plasma half-life is very short (minutes), but CNS effects persist for hours due to BDNF/NGF upregulation cascades.

Reconstitution

Reconstitute a 5mg vial with 2–5mL bacteriostatic water (or sterile saline for intranasal). Swirl gently.

Storage

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations

• Most efficacy data is from Russian clinical literature; Western RCT data is limited.
• Overstimulation, irritability or headache reported at higher doses.
• Intranasal administration may cause transient nasal irritation.